Metabolic Impact of Body Fat Percentage Independent of Body Mass Index in Women with Obesity Remission After Gastric Bypass.
Bariatric surgery
Body fat
Body mass index
Insulin sensitivity
Metabolic syndrome
X-ray absorptiometry
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
14
12
2019
medline:
15
4
2021
entrez:
14
12
2019
Statut:
ppublish
Résumé
Body mass index (BMI) is central when evaluating treatment effect after gastric bypass. The metabolic impact of BMI-independent differences in body fat percentage (BF%) after gastric bypass is not fully understood. We compared metabolic and adipose tissue characteristics in women with high versus low BF% independent of BMI after obesity remission following gastric bypass. A cohort of 215 women was included at baseline. A total of 166 women were re-examined 2 years after gastric bypass, whereof 130 had obesity remission (BMI < 30 kg/m Of the 130 women with obesity remission, 64 had BF% ≥ 35 and 65 < 35. Independent of BMI, high BF% were associated with higher HOMA-IR (P = 0.021), lower M value (P = 0.0046), higher triglycerides (P = 0.013), higher visceral/total and android/gynoid fat mass ratios (P = 0.0032 and 0.0003 respectively), and larger subcutaneous fat cell volume (P < 0.0001) 2 years after gastric bypass. No differences in anthropometric measures, glucose, blood pressure, or fat cell number were observed. Independent of BMI, patients with higher BF% displayed lower insulin sensitivity, higher triglyceride levels, central fat distribution, and larger subcutaneous adipocytes 2 years after gastric bypass. Thus, determination of BF% provides additional information of metabolic characteristics at follow-up of non-obese patients after gastric bypass.
Sections du résumé
BACKGROUND/OBJECTIVE
Body mass index (BMI) is central when evaluating treatment effect after gastric bypass. The metabolic impact of BMI-independent differences in body fat percentage (BF%) after gastric bypass is not fully understood. We compared metabolic and adipose tissue characteristics in women with high versus low BF% independent of BMI after obesity remission following gastric bypass.
SUBJECTS/METHODS
A cohort of 215 women was included at baseline. A total of 166 women were re-examined 2 years after gastric bypass, whereof 130 had obesity remission (BMI < 30 kg/m
RESULTS
Of the 130 women with obesity remission, 64 had BF% ≥ 35 and 65 < 35. Independent of BMI, high BF% were associated with higher HOMA-IR (P = 0.021), lower M value (P = 0.0046), higher triglycerides (P = 0.013), higher visceral/total and android/gynoid fat mass ratios (P = 0.0032 and 0.0003 respectively), and larger subcutaneous fat cell volume (P < 0.0001) 2 years after gastric bypass. No differences in anthropometric measures, glucose, blood pressure, or fat cell number were observed.
CONCLUSIONS
Independent of BMI, patients with higher BF% displayed lower insulin sensitivity, higher triglyceride levels, central fat distribution, and larger subcutaneous adipocytes 2 years after gastric bypass. Thus, determination of BF% provides additional information of metabolic characteristics at follow-up of non-obese patients after gastric bypass.
Identifiants
pubmed: 31832934
doi: 10.1007/s11695-019-04304-6
pii: 10.1007/s11695-019-04304-6
pmc: PMC7347509
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1086-1092Références
J Biol Chem. 1964 Feb;239:375-80
pubmed: 14169133
Mayo Clin Proc. 2011 Jun;86(6):584; author reply 584-5
pubmed: 21628621
Obes Sci Pract. 2015 Oct;1(1):50-58
pubmed: 27721982
Diabetologia. 2010 Dec;53(12):2496-503
pubmed: 20830466
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
Surg Obes Relat Dis. 2018 Jul;14(7):936-942
pubmed: 29705562
Int J Obes (Lond). 2015 Jun;39(6):893-8
pubmed: 25666530
BMJ Open. 2018 Apr 13;8(4):e019200
pubmed: 29654009
Obes Surg. 2016 Aug;26(8):1659-96
pubmed: 27412673
Int J Obes (Lond). 2010 May;34(5):791-9
pubmed: 20125098
FASEB J. 2010 Jan;24(1):326-31
pubmed: 19741173
Obes Surg. 2017 Apr;27(4):1115-1118
pubmed: 28155057
Int J Cardiol. 2013 Jun 5;166(1):111-7
pubmed: 22088224
N Engl J Med. 2017 Feb 16;376(7):641-651
pubmed: 28199805
Front Endocrinol (Lausanne). 2018 Sep 10;9:530
pubmed: 30250454
J Intern Med. 2013 Mar;273(3):219-34
pubmed: 23163728
Obes Surg. 2019 Apr;29(4):1375-1387
pubmed: 30671713
Diabetologia. 2000 Dec;43(12):1498-506
pubmed: 11151758
Lancet. 2015 Sep 5;386(9997):964-73
pubmed: 26369473
Clin Nutr. 2014 Dec;33(6):991-6
pubmed: 24485000
Obesity (Silver Spring). 2012 Jun;20(6):1313-8
pubmed: 22282048
J Intern Med. 2019 Jan;285(1):92-101
pubmed: 30141528
Int J Obes (Lond). 2008 Jun;32(6):959-66
pubmed: 18283284
Int J Obes (Lond). 2012 Feb;36(2):286-94
pubmed: 21587201
IUBMB Life. 2017 Dec;69(12):947-955
pubmed: 29130609
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Diabetes Care. 2017 Jan;40(1):77-84
pubmed: 27852664
Int J Obes (Lond). 2017 Sep;41(9):1379-1387
pubmed: 28584299